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The expression of Lewis blood group antigens depends on 
the alleles inherited at two independent loci, FUT2 (Secre-
tor [SE] gene) and FUT3 (Lewis [LE] gene). The Se and Le 
alleles encode separate fucosyltransferases that interact 
to form Lewis antigens in secretions and fluids. The Lewis 
antigens on RBCs are not integral to the membrane but 
are passively adsorbed from the plasma. The antigens are 
widely distributed in human tissue and fluids and are re-
ceptors for some pathogenic bacteria. Lewis antibodies are 
rarely clinically significant, although there are rare reports 
of hemolytic transfusion reactions, hemolytic disease of the 
fetus and newborn, and renal transplant rejection. This re-
view provides a general overview of the Lewis blood group 
system. An extensive overview by Daniels1 contains addi-
tional detailed information on the Lewis blood group sys-
tem and related antigens.
History
 Anti-Lea was first described in 1946. Mourant2 reported 
a room temperature and 37°C directly agglutinating anti-
body in two women who delivered infants suspected of hav-
ing hemolytic disease of the fetus and newborn (HDFN). 
The RBCs of one of the infants failed to react with the ma-
ternal serum; thus the antibodies were thought to be natu-
rally occurring. This new antibody agglutinated 25 percent 
of 96 RBC samples from English people.
 Two years later, Andresen3 described the original anti-
Leb. This antibody only reacted with group O or A
2
, Le(b+) 
RBCs. Brendemoen4 later reported an anti-Leb that reacted 
with all Le(b+) RBCs regardless of ABO group. The two anti-
bodies described by Andresen and Brendemoen were later 
named anti-LebH and anti-LebL, respectively.5
 In 1948, Grubb6 observed the correlation between the 
Lewis blood groups and Secretor. Twenty Le(a+) adults 
were all nonsecretors of ABH substances and 41 of 42 Le(a–) 
persons were secretors. The Lewis and Secretor loci were 
later shown by family studies to be genetically independent.7 
Grubb and Morgan8 first showed that Lewis substances are 
present in secretions and serum, suggesting that Lewis 
was a system of saliva and plasma antigens.9 Furthermore, 
Lewis antibodies could be neutralized by these soluble sub-
stances.6,10,11 In 1955, Sneath and Sneath12 suggested that 
the fundamental expression of Lewis antigens is in the 
plasma and that RBCs simply adsorb the Lewis antigens 
in vivo. When Le(a+b–) donor RBCs were transfused to 
an Le(a–b+) patient, donor cells separated by differential 
agglutination were found to be Le(a+b+). The transfor-
mation could also be reproduced in vitro. In vitro studies 
also showed the loss of Lewis antigens from Le(a+b–) and 
Le(a–b+) RBCs incubated with plasma from an Le(a–b–) 
donor. Mollison et al.13 demonstrated that the loss of Lewis 
antigens may also occur in vivo. In 1969, Marcus and Cass14 
confirmed that plasma Lewis antigens are glycosphingolip-
ids acquired by the RBC membrane from lipoproteins or 
aqueous dispersions.
 For additional historic information and references, see 
the review by Watkins15 on the early investigations of gly-
coproteins that led to our current understanding of the ge-
netic control, biosynthesis, and phenotypic interactions of 
Lewis, ABO, H, and Secretor.
Genetics and Inheritance
 The six antigens of the Lewis system are listed in 
Table 1. Expression of these antigens is determined by the 
alleles inherited at two independent loci, FUT2 (Secretor 
gene) and FUT3 (Lewis gene) Table 2. The FUT2 allele Se 
encodes a transferase that adds fucose to type 1 precursor 
chains in secretions and fluids to form type 1 H antigen. Be-
cause A and B terminal sugars may be added to type 1 H 
chains, FUT2 also controls A and B antigen expression in 
secretions. The FUT2 allele se is nonfunctional. The FUT3 
allele Le encodes a different transferase that adds a fucose 
on type 1 precursor chains as well as on type 1 H chains. The 
FUT3 allele le is a nonfunctional allele.
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 The phenotype Le(a+b–) is found in non-
secretors (sese), i.e., individuals homozygous 
for a nonfunctional FUT2 allele but who have 
inherited at least one Le allele (Lele or LeLe), 
which results in the fucosylation of type 1 
precursor chains to form Lea antigen (Fig. 1). 
The FUT2 gene controls only H antigen ex-
pression in secretions, not Lewis; therefore, 
individuals with the Le(a+b–) phenotype 
also have Lea in their saliva, but no H.
 The most common Lewis phenotype, 
Le(a–b+), is attributable to inheritance of 
at least one Se allele at the FUT2 locus (SeSe 
or Sese) and one Le allele at the FUT3 locus 
(LeLe or Lele). The Le fucosyltransferase 
adds fucose to type 1 H chains, formed as a 
result of the inheritance of Se, to form Leb 
antigen (Fig. 1). Although small amounts of 
Lea antigen are formed from type 1 chain pre-
cursors, Lea is rarely detectable on the RBCs. 
Lea, Leb, and H antigens are in the saliva, and, 
depending on ABO group, A and B antigens 
as well.
 The Le(a–b–) phenotype is found in in-
dividuals homozygous for a nonfunctional 
Lewis gene (lele). Lewis antigens are absent 
from RBCs and saliva. These individuals may 
be secretors (Sese or SeSe) or nonsecretors (sese) of ABH.
 The Le(a+b+) phenotype is rare in Europeans but oc-
curs in 10 to 40 percent of some Asian populations.16 These 
individuals have at least one Le allele and at least one weak 
or inefficient Se allele (SewSew or Sewse). Sew results in par-
tial or weak secretion of ABH.17
Molecular Basis
 In 1995 Rouquier et al. 18 cloned FUT2 and the pseudo-
gene Sec1. These genes as well as the closely linked, highly 
homologous FUT1 (H gene), which determines H anti-
gen on RBCs, are located on the long arm of chromosome 
19.19,20 The FUT2 gene consists of two exons, with exon 2 
encoding the fucosyltransferase.21 Numerous FUT2 mu-
tations with ethnic associations have been described and 
reviewed.22 Some mutations result in a functional FUT2 
allele (Se), whereas a nonsense mutation, 428G>A (Trp-
143Stop) causes a common nonsecretor allele (se428) in 
Europeans, West Asians, and Africans.19,22 Other non-
secretor alleles with ethnic specificity are caused by single 
and multiple base deletions in FUT2. A missense mutation 
385A>T (Ile129Phe) causes a common enzyme-deficient 
Se allele (Sew385) that is responsible for the Le(a+b+) phe-
notype found in East and Southeast Asians.23 Three null 
FUT2 alleles attributable to gene recombination have been 
observed. One is the sedel allele, which is almost always 
associated with an inactive FUT1 allele (h). Individuals 
homozygous for these alleles (sedelsedel and hh) have the 
classic Indian Bombay phenotype.24
 The Lewis gene (FUT3), located on the short arm of 
chromosome 19,20 was cloned in 1990.25 An intronless cod-
ing region encodes the fucosyltransferase. Silent base sub-
stitutions that result in a functional enzyme and single base 
substitutions that cause the Le(a–b–) phenotype have been 
reviewed.22 Most single base substitutions that cause the 
Le(a–b–) phenotype are enzyme-inactivating, although one 
results in an enzyme with altered substrate specificity.22 As 
with FUT2, many FUT3 mutations show ethnic specificity. 
For more information on FUT2 and FUT3 alleles, see www.
ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/home.26
Biochemistry
 The FUT2 allele Se encodes a transferase that adds a 
terminal α1,2-linked fucose to galactose on type 1 precur-
sor to form type 1 H antigen (Fig. 1). The FUT3 allele Le 
encodes a transferase that adds a subterminal α1,4-linked 
fucose to the N-acetylglucosamine (GlcNAc) of type 1 chain 
precursor to form Lea antigen. The Le enzyme may also add 
α1,4 fucose to the GlcNAc of type 1 H antigen to form Leb 
antigen (Fig. 1). Both Le and Se transferases prefer and 
compete for type 1 chain substrates in secretions and fluids. 
RBC Lewis antigen determinants are plasma glycosphingo-
lipids that are passively adsorbed onto cell membranes,14 
whereas Lewis antigens in secretions are glycoproteins.27
 The Le(a+b–) phenotype occurs in nonsecretors (sese) 
who have at least one Le allele. Nonsecretors do not make 
type 1 H antigen; therefore the Le transferase adds α1,4 fu-
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Fig. 1 Lewis antigen 
biosynthesis. 
A = A transferase;







Le = Le transferase;
R = upstream
carbohydrate;
Se = Se transferase.
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 In the Le(a–b+) phenotype, the Le transferase adds 
α1,4 fucose on type 1 H chain formed as a result of the Se 
transferase. The presence of both α1,2 fucose and α1,4 fu-
cose on GlcNAc results in Leb antigen expression. Although 
the same α1,4 fucose when added to type 1 precursor results 
in Lea antigen, Lea is not expressed on the α1,4 fucosylated 
type 1 H structure (Fig. 1). Most type 1 chain is converted 
to Leb and adsorbed on the RBC membrane, resulting in 
the Le(a–b+) RBC phenotype. However, small amounts 
of Lea antigen are made as a result of the addition of α1,4 
fucose by the Le transferase to type 1 precursor chains be-
fore Se transferase is able to add α1,2 fucose. Once the α1,4 
fucose is added to form Lea, steric hindrance prevents fur-
ther fucosylation by Se transferase (to form Leb) or A and 
B transferases.28 Some monoclonal or potent anti-Lea may 
react with this adsorbed Lea antigen on apparent Le(a–b+) 
RBCs.29
 In the Le(a–b–) phenotype, Lewis antigens are not de-
tectable in saliva or on the RBCs. Nonsecretors (sese and 
lele) produce only type 1 chain precursors. In secretors, 
type 1 H chains will be produced, which can be further fuco-
sylated by A and B transferases (Fig. 1).
 In the Le(a+b+) phenotype, Lea is formed at the expense 
of Leb owing to ineffective competition of the Sew gene prod-
uct for type 1 precursor. This results in more Lea antigen 
and less Leb antigen than is found in individuals with a nor-
mal Se gene.17
 Because Le transferase can add fucose to type 1 H chain 
as well as to type 1 A and type 1 B chains, additional Lewis 
determinants such as ALeb, BLeb, and LebH may be expressed 
depending on an individual’s ABO group (Fig. 1).30,31 These 
antigens are defined by single antibodies, not separable 
mixtures of antibodies. LebH is present on cells with strong 
H antigen expression, i.e., group O and A
2
, Le(b+) RBCs. 
The determinant involves type 1 H antigen and the Le α1,4 
fucose.16 ALeb is formed when Le transferase adds fucose to 
type 1 A chains; BLeb is formed when Le transferase adds 
fucose to type 1 B chains (Fig. 1).
 Leab is a determinant expressed on Le(a+) or Le(b+) 
adult RBCs. The antigen is also present on cord samples 
from infants who have inherited Le, suggesting that the an-
tigen is formed early in embryonic development.16 The com-
mon determinant is within the α1,4 fucose added by the Le 
transferase.32
Infants
 Most newborns type Le(a–b–) during the first month 
of life, although Lewis antigens can sometimes be detected 
on cord RBCs with more sensitive techniques33,34 or the use 
of anti-Leab. If Le is inherited, only very low levels of the Le 
fucosyltransferase are present at the site of production of 
plasma Lewis antigens. The Le fucosyltransferase becomes 
active before the Se fucosyltransferase; therefore Lea devel-
ops first, and RBCs may type as Le(a+b–) followed by a tran-
sient Le(a+b+) phenotype if Se is inherited.33,35 As secretor 
activity increases with age, these infants will ultimately type 
Le(a–b+). By 1 year of age, 50 percent of children express 
their adult phenotype,35 and by age 2, the Lewis phenotype 
of most children will reflect their inherited FUT2 and FUT3 
alleles.36 Lewis antigens are detectable in neonatal saliva. 
As in adults, secretors have Lea and Leb, nonsecretors have 
Lea.35
Pregnancy
 Lewis-positive women may become transiently Le(a–
b–) during pregnancy and may produce Lewis antibod-
ies.29,37 Decreased expression of Lewis antigens during preg-
nancy was first reported by Brendemoen.38 The increased 
incidence of the Le(a–b–) phenotype during pregnancy 
may be a result of increased concentration of plasma lipo-
proteins during pregnancy. In pregnant women, the ratio 
of lipoprotein to RBC mass increases more than fourfold so 
that much more Lewis glycolipid is attached to plasma lipo-
protein than is available for the RBC surface. Leb glycolipid 
in plasma only decreases slightly during pregnancy; there-
fore, decreased expression of Leb on RBCs is not caused by 
decreased blood levels of Leb glycolipid.39
Lewis Antigen Distribution
 Lewis antigens are widely distributed in the human 
body and are often called “histo-blood group antigens.” 
Lewis antigens are found on the pancreas, stomach, and 
large and small intestine mucosa; skeletal muscle; renal 
cortex; and adrenal glands. See Ravn and Dabelsteen40 for 
an extensive review of the tissue distribution of histo-blood 
group antigens.
 In addition to saliva and plasma, Lewis antigens are 
present in other fluids such as human milk,41 urine, gas-
trointestinal juices and seminal fluid,42 ovarian cyst fluid,43 
and amniotic fluid.44 As with RBCs, Lewis antigens on lym-
phocytes14 and platelets45 are acquired from the plasma.
 The gastrointestinal tract may be the primary source of 
plasma Lewis antigens.46 This is evident in a report of eight 
patients with intestinal failure and resections of the ileum 
and or jejunum, all with Le(a–b–) RBCs.47 Recipients of 
bone marrow,48 kidney,49 and liver transplants50 maintain 
their own RBC Lewis phenotypes, suggesting that these 
organs are not primary sources of plasma Lewis antigens.
Antibodies
 Lewis antibodies are most often found in individuals 
with Le(a–b–) RBCs; their sera may contain a mixture of 
anti-Lea, -Leb, and -Leab. Anti-Lea is usually found in Le(a–
b–) individuals who are ABH secretors.51 Le(a–b+) individ-
uals do not make anti-Lea because small amounts of Lea are 
present.
 There are two major types of anti-Leb.  The most com-
mon, anti-LebH, reacts preferentially with Le(b+) RBCs with 
stronger H antigen expression, such as group O or A
2
 RBCs. 
Anti-LebL reacts with all Le(b+) RBCs regardless of ABO 
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group.  Anti-Leb is usually found in Le(a–b–) individuals 
who are nonsecretors of ABH.51 Anti-Leb is rarely produced 





B with anti-LebH.4, 52,53   
 Other Lewis antibodies include anti-ALeb and -BLeb 
which react with the compound antigens on group A or B 
RBCs. Anti-Leab occurs mainly in Le(a–b–) secretors who 
are group A
1
, B, or A
1
B.  This antibody reacts with Lewis-
positive RBCs from adults as well as cord RBCs from in-
fants with an Le allele.16
 Most Lewis antibodies are naturally occurring IgM. 
Some may have an IgG component,54–56 and there are rare 
examples of pure IgG Lewis antibodies.57 Although most 
Lewis antibodies are naturally occurring, some may be 
stimulated by RBC transfusion. Cheng and Lukomskyi58 
reported on two patients who exhibited Lewis antibodies 
after massive RBC transfusions of presumably Lewis-
positive units. One patient exhibited IgG anti-Lea and the 
other had IgM and IgG anti-Leb. There was no evidence of 
hemolysis in either patient.
 In patients with 37°C reactive anti-Lea or anti-Leb, the 
antibody titer may rise after RBC transfusion.13,59,60 In spite 
of this, Lewis antibodies are rarely implicated in hemolytic 
transfusion reactions. Anti-Lea is more frequently associ-
ated with acute hemolytic transfusion reactions61-64 than is 
anti-Leb.65,66 Three cases of delayed hemolytic transfusion 
reactions (DHTR) have been claimed.67–69 Hemolytic trans-
fusion reactions are rare because most Lewis antibodies are 
not active at 37°C, transfused RBCs lose their Lewis anti-
gens into the recipient’s plasma, and there is neutralization 
of recipient Lewis antibodies by Lewis substance in donor 
plasma before the antibodies can bind to the RBCs of the 
recipient.13,59
 Because most Lewis antibodies are IgM, they react best 
in agglutination tests at room temperature and occasion-
ally in agglutination tests at 37°C. Reactivity with anti-
human globulin (AHG) may be related to IgG or caused 
by bound complement if polyspecific AHG reagent is used. 
Lewis antibodies may demonstrate complement activation 
by causing in vitro lysis of Lewis-positive RBCs, especially 
with the use of enzyme-treated RBCs or fresh serum. To 
aid Lewis antibody detection and identification, plasma 
and saliva Lewis substances or commercial sources of solu-
ble substances may be used to neutralize Lewis antibodies, 
and enzyme-treated RBCs may be used to enhance Lewis 
antibody reactivity.
 Transfusion services vary in their selection of RBC 
units for patients with Lewis antibodies. Some provide 
antigen-negative units if Lewis antibodies are hemolytic 
in vitro, agglutinating at 37°C or reacting in the IAT with 
anti-IgG. In general, however, the selection of antiglobulin 
crossmatch-compatible blood for patients with Lewis anti-
bodies is recommended and considered safe.70,71
 Lewis antibodies rarely cause HDFN. Although most 
are IgM and cannot cross the placenta, IgG Lewis antibodies 
are frequently detected and may cross the placenta. Spital-
nik et al. 55 detected IgG anti-Lea by hemagglutination in 13 
of 13 maternal samples and in 12 of the 13 cord samples by 
enzyme-linked immunosorbent assay. They concluded that 
the rare incidence of HDFN is attributable to poor expres-
sion of Lewis antigens on fetal cells instead of the frequently 
cited low incidence of IgG Lewis antibodies.
 Two cases of mild HDFN caused by Lewis antibodies 
have been reported. The first reported case attributable to 
anti-Lea caused a positive DAT with anti-Lea in the eluate 
and hyperbilirubinemia. The infant’s RBCs initially typed 
as Le(a–b+), which was speculated to be caused by blocking 
of the antigen by the maternal antibody. Four days later the 
RBCs typed Le(a+b+) The 42-week gestation was speculat-
ed to have allowed stronger development of Lea antigen, and 
the mildness was thought to be caused by partial neutraliza-
tion of the maternal antibody by Lea substance in the fetal 
plasma.72 Neonatal jaundice developed in a case of HDFN 
caused by anti-Leb. The antibody was IgM and IgG and was 
hemolytic in vitro. An eluate prepared from the newborn’s 
DAT-positive RBCs contained anti-Leb.73
Clinical Significance
 Lewis antigens are receptors for pathogenic bacteria. 
In particular, Leb and type 1 H mediate attachment of Helico-
bacter pylori,74 a gram-negative bacterium associated with 
gastritis, gastric and duodenal ulcers, adenocarcinoma,75 
and immune thrombocytopenic pupura.76 Leb and type 1 
H are also receptors for Norwalk virus that causes gastro-
enteritis.77 Conversely, lack of Lewis antigens, i.e., the 
Le(a–b–) phenotype, is associated with an increased suscep-
tibility to infections by Candida spp,78 and uropathogenic 
Escherichia coli.79
 The Le(a–b–) phenotype is also associated with an in-
creased risk of cardiovascular disease.80 The mechanism for 
this association is unclear, but it may be mediated through 
elevated triglycerides,80 insulin resistance syndrome,81 or 
obesity,82 each of which is also associated with the Le(a–b–) 
phenotype.
 The Le(a–b–), Bombay phenotype occurs in patients 
with leukocyte adhesion deficiency syndromes (LADII). 
A mutation in the GDP-fucose transporter results in 
hypofucosylation of glycoproteins. Clinically, these pa-
tients have leukocytosis, severe infections, and mental and 
growth retardation, thereby demonstrating the broad im-
pact of glycoprotein fucosylation.83,84
 The role of Lewis in renal transplantation is contro-
versial. Oriol et al.85 reported that Lewis-negative renal al-
lograft recipients have a significantly lower graft survival 
rate than do Lewis-positive recipients. Other investigators 
have found that renal transplant recipients who receive a 
Lewis-matched kidney have the best survival.86–88 Although 
these reports suggest that cytotoxic Lewis antibodies may 
play a role in renal transplant survival, other investigators 
have reported that Lewis phenotype compatibility does not 
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affect survival.89,90 Detectable Lewis antibodies in renal 
transplant recipients, however, have been associated with 
antibody-mediated graft rejection.91-93
 In summary, the Lewis blood group system is inter-
esting and complex; the antigens are widely distributed in 
human tissue and fluid; and the expression of most Lewis 
antigens requires the interaction of transferases from more 
than one blood group system. Lewis antibodies are rarely 
clinically significant; however, there is growing evidence 
that the presence or absence of Lewis antigens in an indi-
vidual can be clinically significant, and this is the focus of 
much of the current research and investigation involving 
the Lewis blood group system.
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